Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOXYVAC: Doxycycline PEP and Bexsero Vaccine for STI Prevention in MSM
NCT04597424Phase 3Completed
- Sponsor
- ANRS
- Start
- Jan 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of doxycycline, meningococcal group B vaccine in sexually transmitted infection (STI), Chlamydia trachomatis infection (CT), syphilis, gonorrhea, sponsored by ANRS. Started Jan 2021; status: completed.
02
Drugs
doxycyclinemeningococcal group B vaccine
03
Conditions
sexually transmitted infection (STI)Chlamydia trachomatis infection (CT)syphilisgonorrhea
Beyond the preview
Go deeper on NCT04597424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04597424.